- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cystic fibrosis
- Meeting Date: December 2021
- Public Summary Document (PSD) December 2021 PBAC Meeting - (PDF 843KB)
- Public Summary Document (PSD) December 2021 PBAC Meeting - (Word 223KB)
Lumacaftor + ivacaftor – December 2021
Lumacaftor + ivacaftor: Tablet containing lumacaftor 100 mg with ivacaftor 125 mg; Orkambi®
Last updated
14 April 2022